3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
6
Withdrawn
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
46
Stomach Neoplasms
10
Neoplasms
10
Colorectal Neoplasms
8
Neoplasm Metastasis
7
HER2-positive Breast Cancer
7
Esophageal Neoplasms
5
Triple Negative Breast Neoplasms
4
Salivary Gland Neoplasms
3
Ovarian Neoplasms
3
Lung Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Adenocarcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Pathologic Complete Response
2
Pancreatic Neoplasms
2
Multiple Myeloma
2
Meningeal Neoplasms
2
Lymphoma, Non-Hodgkin
2
Hematologic Neoplasms
2
HER2-positive Early Breast Cancer
2
Colonic Neoplasms
2
Biliary Tract Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Adenocarcinoma Of Esophagus
2
Urinary Bladder Neoplasms
1
Solid Tumor, Adult
1
Skin Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Interventions
Magnetic Resonance Spectroscopy
51
Specimen Handling
42
enzalutamide
35
Androgen Antagonists
34
Radiosurgery
32
Radiotherapy
31
Prednisone
26
darolutamide
24
Abiraterone Acetate
24
Leuprolide
22
Docetaxel
22
apalutamide
20
Pluvicto
19
abiraterone
18
Standard of Care
18
Triptorelin Pamoate
17
Radiation
17
Biopsy
16
relugolix
15
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
15
Goserelin
14
Blood Specimen Collection
13
gallium 68 PSMA-11
12
pembrolizumab
11
X-Rays
11
Surveys and Questionnaires
11
luprolide acetate gel depot
10
Carboplatin
10
Methods
9
Interviews as Topic
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Prostatic Neoplasms
×
Trastuzumab
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled